跳至主要内容
临床试验/NCT07120997
NCT07120997招募中不适用

A Prevention Strategy for the Indication of Prune Consumption in Perimenopausal Females: Can Prunes Attenuate Bone Loss?

Penn State University1 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2025年12月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
124
试验地点
1
主要终点
Percent change from baseline in areal bone mineral density (via DXA) of the lumbar spine, total hip, and femoral neck

研究概览

简要总结

Dietary interventions of prune consumption during the transmenopausal period are innovative methods to prevent bone loss. Modern medicine does not intervene to prevent or attenuate this highly vulnerable period of bone loss which, if successfully attenuated, can potentially prevent/delay osteoporosis in women. The transmenopausal period represents an opportunistic window for the study because bone loss is at its greatest at this time, with females losing as much as 6-7% of bone. If this project is successful at attenuating bone loss, it can immediately be disseminated to the public to promote prune consumption to slow down and attenuate perimenopausal bone loss. As such, this project could improve the long-term bone health of females and avoid or delay osteoporosis and improve quality of life. The long-term goal of this study is to test the novel hypothesis that prune consumption for 18 months during the 3-year transmenopausal period prevents the dramatic rate of bone loss in perimenopausal females during a window of heightened physiological vulnerability. At Penn State University, the study will compare the effects of 18 months of daily dietary consumption of 50 g of prunes (5-6) versus a no-prune control group on bone outcomes (bone mineral density, bone geometry), mechanistic factors (bone and inflammatory markers, inflammatory response of ex vivo cultured peripheral blood mononuclear cells, monocytes), and gut microbiome.

详细描述

Females spend at least one-third of their lifespan after menopause, therefore strategies that improve the long-term health of women and engage a prevention strategy to improve health are warranted and represent opportunities for high impact and high return on investment. After menopause, one in two females will suffer a fragility fracture in their lifetime, and the mortality rate after a hip fracture is as high as 25%. Moreover, since osteoporosis-related treatment costs more than $100 billion worldwide, strategies that focus on the prevention of osteoporosis-related fragility fractures are warranted. As such, the prevention of bone loss, osteoporosis, and its related fractures is much preferred over treatment of osteoporosis given the high costs, negative side effects, and poor compliance to pharmacological treatment regimens. Therefore, research addressing the optimization of the health of perimenopausal females to delay chronic disease is very much necessary and represents the overall objective of this project. Given the high mortality rate of hip fractures, this intervention may potentially save people's lives while reducing a significant healthcare burden.

The long-term goal of this project is to change the course of bone loss during a very specific and opportunistic intervention window, i.e., the transmenopausal window. This window of intervention is opportunistic because females lose more bone at the hip and spine than at any other time; that is, as much as 6% and 7% at the hip and spine, respectively. In fact, the amount of bone loss during this three-year transmenopausal window that initiates late perimenopause is greater than the amount of bone loss observed during the postmenopause window, when the latter is defined as 2 to 5 years after the final menstrual period. The STRAW+10 investigators defined the stages of menopause, including the transmenopause period, a stage in life that is associated with dramatic bone loss. As such, this project is novel, innovative, and can potentially delay the serious effects of osteoporotic bone loss and associated fractures, to which transmenopausal bone loss significantly contributes. When one considers that as of 2021, there were approximately 1.02 billion females over 50 years of age worldwide, with an estimated 1.2 billion females over the age of 50 by 2030, accounting for 26% of all females worldwide, the potential impact of this project is substantial. Indeed, this project may affect the long-term picture of bone health for millions of females by delaying or attenuating the acceleration of bone loss during the transmenopause period. Moreover, since osteoporosis affects millions of females worldwide, this project has the potential to offset the devasting long-term effects of accelerated bone loss during transmenopause that is associated with osteoporosis.

The overall objective of this research is to test whether prunes are effective in attenuating the rapid transmenopausal bone loss observed in late peri and early postmenopausal females. The investigators will study the effects of 18 months of prune consumption in females recruited during the late peri and early postmenopausal stage, allowing a high probability for data collection spanning the transmenopausal period of heightened bone loss, i.e., 12 months before the final menstrual period and the two years following the final menstrual period. The investigators will also examine the physiological mechanisms underlying the bone trophic effects of prune consumption to seek evidence on how prunes work. If successful, prunes will be demonstrated to be a powerful strategy to attenuate and delay the rapid decline in bone mineral density and decrements in microarchitecture that eventually lead to osteoporosis and heightened risk for fracture.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
44 Years 至 55 Years(Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Age 44 to 55 years
  • •Not severely obese (BMI <35 kg/m^2)
  • •Healthy (determined by a screening questionnaire, physical and medical history by a certified nurse practitioner, complete metabolic panel, and complete blood count)
  • •Willing to include prunes in their daily diet
  • •Not taking any natural dietary supplement containing phenolics, i.e.,< 1 cup/day of blueberries or apples for at least 2 months prior to study entry
  • •Non-smoking
  • •Ambulatory
  • •No menses for ≥60 days but not more than 18 months post final menstrual period
  • •Only participants who have a determinable natural (not surgical) final menstrual period date are eligible

排除标准

  • •Subjects who regularly consume prunes, dried apples, prune juice, or heavy consumers of blueberries (1 cup or more/day)
  • •History of vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis after age 45 yr)
  • •Untreated hyper- or hypothyroidism
  • •Current hyper- or hypoparathyroidism
  • •Significantly impaired renal function
  • •Current hypo- or hypercalcemia
  • •History of spinal stenosis
  • •History of heart attack, stroke, thromboembolism, kidney disease, malabsorption syndrome, or seizure disorders
  • •Positive for HIV, Hep-C or Hep-B surface antigen and malignancy
  • •Use of the following agents affecting bone metabolism: intravenous bisphosphonates at any time; fluoride (for osteoporosis) within the past 24 months; denosumab at any time; bisphosphonates, parathyroid hormone or strontium within the past 12 months; calcitonin; selective estrogen receptor modulators within the past 12 months; systemic oral or transdermal estrogen within the past 3 months; systemic glucocorticosteroids (≥ 5 mg prednisone equivalent per day for more than 10 days); or tibolone within the past 3 months
  • •Hormonal contraception within the past three months
  • •Subjects who will not consume study provided dietary items or who will not stop taking their own natural product supplements

研究组 & 干预措施

Calcium and Vitamin D - Control group

Experimental

Participants will take calcium and vitamin D supplements daily for a baseline period and for the duration of the intervention. Participants will be asked to refrain from consumption of prunes and fruits that have high phenolic content for the duration of the intervention (18 months).

干预措施: Vitamin D Supplement (Dietary Supplement)

50g Prunes, Calcium, and Vitamin D - Intervention Group

Experimental

Participants will take calcium and vitamin D supplements daily for a baseline period and for the duration of the intervention. Additionally, participants will be provided with prunes and asked to consume 6 (50g) prunes per day for the duration of the intervention (18 months).

干预措施: Prunes (Dietary Supplement)

50g Prunes, Calcium, and Vitamin D - Intervention Group

Experimental

Participants will take calcium and vitamin D supplements daily for a baseline period and for the duration of the intervention. Additionally, participants will be provided with prunes and asked to consume 6 (50g) prunes per day for the duration of the intervention (18 months).

干预措施: Vitamin D Supplement (Dietary Supplement)

50g Prunes, Calcium, and Vitamin D - Intervention Group

Experimental

Participants will take calcium and vitamin D supplements daily for a baseline period and for the duration of the intervention. Additionally, participants will be provided with prunes and asked to consume 6 (50g) prunes per day for the duration of the intervention (18 months).

干预措施: Calcium supplement (Dietary Supplement)

Calcium and Vitamin D - Control group

Experimental

Participants will take calcium and vitamin D supplements daily for a baseline period and for the duration of the intervention. Participants will be asked to refrain from consumption of prunes and fruits that have high phenolic content for the duration of the intervention (18 months).

干预措施: Calcium supplement (Dietary Supplement)

结局指标

主要结局

Percent change from baseline in areal bone mineral density (via DXA) of the lumbar spine, total hip, and femoral neck

时间窗: Baseline, month 9, month 18

Percent change in areal bone mineral density measured at baseline, month 9, and month 18 of the 18-week dietary intervention at the lumbar spine, total hip, and femoral neck.

次要结局

  • Changes from baseline in Spine Trabecular Bone Score (TBS) (via DXA)(Baseline, month 9, and month 18)
  • Percent change from baseline in volumetric BMD of the tibia and radius (via pQCT)(Baseline, month 9, and month 18)
  • Percent change from baseline in bone geometry measurements of the tibia and radius (via pQCT)(Baseline, month 9, and month 18)
  • Percent change from baseline in bone strength index of the tibia and radius (via pQCT)(Baseline, month 9, and month 18)
  • Percent change from baseline in stress strain index of the tibia and radius (via pQCT)(Baseline, Month 9, Month 18)
  • Percent change from baseline in polar moment of inertia measurements of the tibia and radius (via pQCT)(Baseline, Month 9, Month 18)
  • Change from baseline in C-terminal telopeptide of type I collagen (CTx)(Baseline, month 9, and month 18)
  • Change from baseline in Tartrate-resistant acid phosphatase (Trap 5b)(Baseline, month 9, and month 18)
  • Change from baseline in expression of inflammatory markers(Baseline, month 9, and month 18)
  • Change from baseline in gut permeability(Baseline, month 9, and month 18)
  • Change from baseline in gut microbiome(Baseline, month 9, and month 18)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mary Jane DeSouza

Distinguished Professor of Kinesiology and Physiology

Penn State University

研究点 (1)

Loading locations...

相似试验